Generation of chemoattractant substances is believed to play an important role in the development and outcome of infectious and allergic processes. Recent studies have attracted attention to chemoattractant activities of substances such as LPC (lysophosphatidylcholine), HETEs (5-hydroxy or 12-hydroxy eicosatetraeonic acid) and leukotrienes which are derived from membrane phospholipids. Accordingly, we have initiated an immunological and biochemical investigation with the purpose of: (1) Conducting further studies of lysophosphatidylcholine, a newly recognized chemoattractant for lymphocytes, and (2) investigating a new aspect of complement-induced inflammation by assessing the role of complement proteins C5b-9 in the generation of LPC, HETEs, leukotrienes and, possibly, other chemoattractants from membrane phospholipids. With respect to LPC we want to determine what cell types respond to its attractant activity, what role it plays in vivo as a mediator of inflammation, what structural analogs of LPC exhibit chemoattractant activity, whether LPC is converted to other chemoattractants by responding cells, and whether LPC can induce formation of new chemoattractants including some arachidonate metabolites with known chemoattractant activity. With respect to complement, we want to determine what cell types produce chemoattractant factors when attacked by C5b-9 and to assess formation of LPC, HETEs, leukotrienes and, possibly, other chemoattractants. We expect that these efforts will expand knowledge of complement-induced inflammation beyond the well-known activities of complement fragments C3a, C4a, C5a, and C3b. We believe that activation of complement at tissue sites of infection, allergy and malignancy, is likely to lead to membrane damage which could activate membrane-associated phospholipase and other enzymes that are instrumental in producing chemoattractant phospholipid derivatives, including LPC.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI019826-05
Application #
3129262
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1983-12-01
Project End
1989-05-31
Budget Start
1987-12-01
Budget End
1989-05-31
Support Year
5
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Nishijima, J; Wright, T M; Hoffman, R D et al. (1989) Lysophosphatidylcholine metabolism to 1,2-diacylglycerol in lymphoblasts: involvement of a phosphatidylcholine-hydrolyzing phospholipase C. Biochemistry 28:2902-9
Wright, T M; Hoffman, R D; Nishijima, J et al. (1988) Leukocyte chemoattraction by 1,2-diacylglycerol. Proc Natl Acad Sci U S A 85:1869-73
Wright, T M; Rangan, L A; Shin, H S et al. (1988) Kinetic analysis of 1,2-diacylglycerol mass levels in cultured fibroblasts. Comparison of stimulation by alpha-thrombin and epidermal growth factor. J Biol Chem 263:9374-80
Drysdale, B E; Agarwal, S; Shin, H S (1988) Macrophage-mediated tumoricidal activity: mechanisms of activation and cytotoxicity. Prog Allergy 40:111-61
Agarwal, S; Drysdale, B E; Shin, H S (1988) Tumor necrosis factor-mediated cytotoxicity involves ADP-ribosylation. J Immunol 140:4187-92
Drysdale, B E; Yapundich, R A; Shin, M L et al. (1987) Lipopolysaccharide-mediated macrophage activation: the role of calcium in the generation of tumoricidal activity. J Immunol 138:951-6
Shirazi, Y; Imagawa, D K; Shin, M L (1987) Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes. J Neurochem 48:271-8
Imagawa, D K; Barbour, S E; Morgan, B P et al. (1987) Role of complement C9 and calcium in the generation of arachidonic acid and its metabolites from rat polymorphonuclear leukocytes. Mol Immunol 24:1263-71
Imagawa, D K; Osifchin, N E; Ramm, L E et al. (1986) Release of arachidonic acid and formation of oxygenated derivatives after complement attack on macrophages: role of channel formation. J Immunol 136:4637-43